BAUSCH + LOMB CORP
BLCONYSETrading Snapshot
- Day Range
- $465.22 – $474.13
- 52-Week Range
- $13.77 – $18.92
- Volume
- $2.61B
- Avg Volume
- $3.07B
- Shares Outstanding
- 357.2M
- Next Earnings
- Dec 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $5.10B
- Last Q Revenue
- $1.39B
- P/E Ratio
- -35.8
- P/S Ratio
- 1.2x
- EPS (TTM)
- $-0.48
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.7%
Why Investors Own BLCO
- ✓High-growth profile — revenue up +40.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BAUSCH + LOMB CORP
BLCO
StockOtter · stockotter.spaceAbout BAUSCH + LOMB CORP
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
BAUSCH + LOMB CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift BLCO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
BAUSCH + LOMB CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.